← Back to Search

Behavioral Intervention

Contingency Management for Anosognosia

N/A
Waitlist Available
Led By Martin Paulus, MD
Research Sponsored by Laureate Institute for Brain Research, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Age 18-65 years old
2. Diagnosis of Schizophrenia Spectrum, Bipolar, or Related Disorders
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

Summary

This study aims to determine the feasibility and effectiveness of implementing a contingency management program in a small group of mentally ill, unhoused individuals with schizophrenia or bipolar disorder and anosognosia (a lack of insight into their mental health) in the City of Tulsa. The primary objective of the study is to decrease disruptive or problematic behaviors (e.g. interactions with police, emergency services, hospitals, shelter staff, 911 calls) by unhoused individuals in the community through monetary incentives. Up to 15 participants will meet weekly for 30 minutes with their case manager to discuss progress on life goals ($10) and for having seven days with no disruptive behaviors (or "trouble-free days") per week at each visit, they will receive an additional baseline payment of $20, increasing with continued success in subsequent weeks by $1 per week.

Who is the study for?
This trial is for unhoused individuals in Tulsa with schizophrenia or bipolar disorder who also have anosognosia, meaning they're not aware of their mental health condition. Participants should display problematic behaviors and will work with a case manager weekly.
What is being tested?
The study tests if giving money can help reduce disruptive behaviors in the participants. They get $10 for discussing life goals and an extra $20 for trouble-free weeks, which increases by $1 each successful week.
What are the potential side effects?
Since this trial involves monetary incentives rather than medication, traditional side effects are not expected. However, there may be psychological impacts from receiving or failing to receive the incentives.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Reduction in disruptive behaviors

Trial Design

1Treatment groups
Experimental Treatment
Group I: Contingency ManagementExperimental Treatment1 Intervention
Meet weekly for 30 minutes with their case manager to discuss progress on life goals ($10) and for having seven days with no disruptive behaviors (or "trouble-free days") per week at each visit, they will receive an additional baseline payment of $20, increasing with continued success in subsequent weeks by $1 per week.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency Management
2014
Completed Phase 2
~3430

Find a Location

Who is running the clinical trial?

Laureate Institute for Brain Research, Inc.Lead Sponsor
52 Previous Clinical Trials
5,425 Total Patients Enrolled
Tulsa Day CenterUNKNOWN
Martin Paulus, MDPrincipal InvestigatorLaureate Institute for Brain Research
1 Previous Clinical Trials
75 Total Patients Enrolled
~7 spots leftby Sep 2025